Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$380.79 USD

380.79
59,316

+5.85 (1.56%)

Updated Aug 7, 2025 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Boston Scientific to Buy Cryterion Medical to Widen EP Suite

by Zacks Equity Research

Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

    Zacks Equity Research

    Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

    by Zacks Equity Research

    We are upbeat about Bio-Rad's (BIO) solid growth in geographies like North America, China and Asia Pacific.

      Zacks Equity Research

      Here's Why You Should Invest in Baxter (BAX) Stock Right Now

      by Zacks Equity Research

      Baxter's (BAX) raised 2018 guidance and strong international presence make it a lucrative pick.

        Zacks Equity Research

        Insulet Omnipod Insulin Pump Finds Favor in British Columbia

        by Zacks Equity Research

        Insulet's (PODD) Omnipod has huge market potential in Canada as it is the only tubeless insulin pump sold in the region.

          Zacks Equity Research

          Here's Why You Should Invest in Masimo (MASI) Right Now

          by Zacks Equity Research

          Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.

            Zacks Equity Research

            Insulet Starts European Direct Operation, Braces Global Base

            by Zacks Equity Research

            Insulet's (PODD) goal to begin direct commercial operation in Europe is a year-long endeavor.

              Zacks Equity Research

              Henry Schein's JV With Internet Brands to Boost Dental Arm

              by Zacks Equity Research

              Henry Schein (HSIC) and Internet Brands' newly formed JV is likely to deliver integrated dental technology for improving practice management, marketing as well as patient communication.

                Zacks Equity Research

                Integer Holdings Offloads AS&O, Focuses on Cardiac Units

                by Zacks Equity Research

                Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.

                  Zacks Equity Research

                  Insulet Banks on Omnipod's Growing Market Reach, Runs Risks

                  by Zacks Equity Research

                  We are upbeat about the solid uptake of Insulet's (PODD) Omnipod System in the United States and other geographies.

                    Zacks Equity Research

                    Here's Why You Should Hold Wright Medical (WMGI) Stock Now

                    by Zacks Equity Research

                    Here we take a quick look at the major factors that have been plaguing Wright Medical and discuss the prospects that ensure near-term recovery.

                      Zacks Equity Research

                      Here's Why You Should Invest in Align Technology (ALGN) Now

                      by Zacks Equity Research

                      We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions.

                        Zacks Equity Research

                        Stryker or Baxter: Which is a Better Pick for Your Portfolio?

                        by Zacks Equity Research

                        Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.

                          Zacks Equity Research

                          Here's Why You Should Add Abaxis (ABAX) to Your Portfolio

                          by Zacks Equity Research

                          We are upbeat about Abaxis' (ABAX) solid consumable and instrument sales growth along with strength in the medical and veterinary market segments.

                            Zacks Equity Research

                            Here's Why You Should Hold Varian Medical (VAR) Stock Now

                            by Zacks Equity Research

                            Here we analyze the major factors that have been plaguing Varian Medical (VAR) and discuss the prospects that ensure near-term recovery.

                              Zacks Equity Research

                              McKesson (MCK) Issues Strong Preliminary Results for Q1

                              by Zacks Equity Research

                              McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.

                                Zacks Equity Research

                                Stryker (SYK) to Acquire SafeAir, Reduce Surgical Smoke

                                by Zacks Equity Research

                                The acquisition of SafeAir likely to boost Stryker's (SYK) core MedSurg and Neurotechnology segments.

                                  Zacks Equity Research

                                  Align Scripts New Success in EMEA, Lifts Global Progress

                                  by Zacks Equity Research

                                  Align (ALGN) attains a significant milestone with accelerated adoption of Invisalign clear aligner therapy.

                                    Zacks Equity Research

                                    Here's Why You Should Hold on to Becton, Dickinson Stock Now

                                    by Zacks Equity Research

                                    Becton, Dickinson (BDX) gains from strong fundamentals. Recent product recall issues raise concern.

                                      Zacks Equity Research

                                      Integra LifeSciences Global Prospects Solid, Competition Rife

                                      by Zacks Equity Research

                                      Integra LifeSciences (IART) continues to expand overseas.

                                        Zacks Equity Research

                                        Pra Health Grows Organically, Symphony Synergies a Positive

                                        by Zacks Equity Research

                                        The $530-million Symphony buyout buoys hope for PRA Health (PRAH). The move is likely to improve its ability in the clinical research and commercial development process via data and analytics tools.

                                          Zacks Equity Research

                                          Here's Why You Must Add STERIS (STE) to Your Portfolio Now

                                          by Zacks Equity Research

                                          STERIS' (STE) acquisition of U.K.-based outsourced sterilization services provider, Synergy Health plc, remains one of its key strategic moves.

                                            Zacks Equity Research

                                            Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks

                                            by Zacks Equity Research

                                            The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.

                                              Zacks Equity Research

                                              Opko Health (OPK) Rallies on Q1 Earnings and Revenue Beat

                                              by Zacks Equity Research

                                              Opko Health (OPK) gains from solid pharmaceutical business in the first quarter of 2018.

                                                Zacks Equity Research

                                                IDEXX Laboratories Global Growth Solid on Catalyst Uptake

                                                by Zacks Equity Research

                                                IDEXX (IDXX) steadily demonstrates strong organic growth, driven by solid sales at the Companion Animal Group (CAG) business, fueled by a firm global Catalyst uptake.

                                                  Zacks Equity Research

                                                  New Indication for Medtronic's Bone Cement Gets 510(K) Nod

                                                  by Zacks Equity Research

                                                  Medtronic (MDT) to broaden its commitment to the therapy of pathological fractures of the vertebral body on the back of its expanded indication for Kyphon HV-R Bone Cement.